Allocryptopine
Based on 1 Customer Validation
Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current.
For research use only. We do not sell to patients.
- Purity: 99.53%
- CAS No.: 485-91-6
- Formula: C21H23NO5
- Molecular Weight:369.41
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| GES1 | IC50 |
>150 μM
Compound: 11
|
Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 35286954] |
| HGC-27 | IC50 |
97.8 μM
Compound: 11
|
Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 35286954] |
| KB | IC50 |
>338 μM
Compound: Allocrytopine
|
Cytotoxicity against human KB cells after 72 hrs
Cytotoxicity against human KB cells after 72 hrs
|
[PMID: 11141105] |
| MGC-803 | IC50 |
109.2 μM
Compound: 11
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 35286954] |
Chemical Information
-
CAS No. 485-91-6
-
Appearance Solid
-
Molecular Weight 369.41
-
Formula C21H23NO5
-
Color White to off-white
-
SMILES
O=C1C(C(CCN(C)CC2=C(OC)C(OC)=CC=C2C1)=C3)=CC4=C3OCO4
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 50 mg/mL (135.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Xu B, et al. Effect of α-Allocryptopine on Delayed Afterdepolarizations and Triggered Activities in Mice Cardiomyocytes Treated with Isoproterenol. Evid Based Complement Alternat Med. 2015;2015:634172. [Content Brief]
[2]. Lin K, et al. Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells. Acta Pharmacol Sin. 2013 Jun;34(6):847-58. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7070 mL | 13.5351 mL | 27.0702 mL | 67.6755 mL |
| 5 mM | 0.5414 mL | 2.7070 mL | 5.4140 mL | 13.5351 mL | |
| 10 mM | 0.2707 mL | 1.3535 mL | 2.7070 mL | 6.7675 mL | |
| 15 mM | 0.1805 mL | 0.9023 mL | 1.8047 mL | 4.5117 mL | |
| 20 mM | 0.1354 mL | 0.6768 mL | 1.3535 mL | 3.3838 mL | |
| 25 mM | 0.1083 mL | 0.5414 mL | 1.0828 mL | 2.7070 mL | |
| 30 mM | 0.0902 mL | 0.4512 mL | 0.9023 mL | 2.2558 mL | |
| 40 mM | 0.0677 mL | 0.3384 mL | 0.6768 mL | 1.6919 mL | |
| 50 mM | 0.0541 mL | 0.2707 mL | 0.5414 mL | 1.3535 mL | |
| 60 mM | 0.0451 mL | 0.2256 mL | 0.4512 mL | 1.1279 mL | |
| 80 mM | 0.0338 mL | 0.1692 mL | 0.3384 mL | 0.8459 mL | |
| 100 mM | 0.0271 mL | 0.1354 mL | 0.2707 mL | 0.6768 mL |